CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy-Reference-Cited by-同舟云学术

CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy

Published:2020-11-20 Issue:47 Volume:6 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Rosenblum Daniel¹²³⁴^ORCID,Gutkin Anna¹²³⁴^ORCID,Kedmi Ranit¹²³⁴⁵^ORCID,Ramishetti Srinivas¹²³⁴,Veiga Nuphar¹²³⁴,Jacobi Ashley M.⁶^ORCID,Schubert Mollie S.⁶^ORCID,Friedmann-Morvinski Dinorah⁷^ORCID,Cohen Zvi R.⁸,Behlke Mark A.⁶^ORCID,Lieberman Judy⁹^ORCID,Peer Dan¹²³⁴^ORCID

Affiliation:

1. Laboratory of Precision Nanomedicine, The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel-Aviv, Israel.

2. Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv, Israel.

3. Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, Israel.

4. Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel.

5. Molecular Pathogenesis Program, The Kimmel Center for Biology and Medicine of the Skirball Institute, New York University School of Medicine, New York, NY 10016, USA.

6. Integrated DNA Technologies Inc., Coralville, IA 52241, USA.

7. Sagol School of Neuroscience, Department of Biochemistry and Molecular Biology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.

8. Department of Neurosurgery, Sheba Medical Center, Ramat-Gan, and Sackler School of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.

9. Program in Cellular and Molecular Medicine, Boston Children’s Hospital, and Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.

Abstract

CRISPR lipid nanoparticles promote in vivo therapeutic genome editing in two aggressive cancer mouse models.

Funder

ICRF

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference50 articles.

1. Evolution of acquired resistance to anti-cancer therapy

2. What does not kill a tumour may make it stronger: In silico insights into chemotherapeutic drug resistance

3. Development and Applications of CRISPR-Cas9 for Genome Engineering